Advertisement

Comment to Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease; an individual patient data analysis of three clinical trials

  • Christiane MatuschekEmail author
  • David Krug
  • Rainer J. Klement
  • René Baumann
Letter to the Editor
  • 54 Downloads

Abdel-Rahman [1] analyzed the overall survival-rate and disease-free survival of T1-2 N1 breast cancer patients after mastectomy, who were adjuvantly treated with various modern chemotherapeutic drugs (anthracyclines, taxanes) in 3 prospective phase III chemotherapy trials. His analysis suggested no potential benefits of an additional adjuvant postmastectomy radiotherapy (PMRT). The included trials were the BIG 02/98 [6], the BCIRG 001 [7] and the BCIRG-005 [5] trials. The author concludes that in T1-2 N1 breast cancer patients who have received modern chemotherapy drugs PMRT does not provide any benefit for overall and disease-free survival. Prospective studies are necessary.

Comment

PMRT has shown a survival benefit in many randomized trials and meta-analyses, in addition to a reduction in locoregional recurrence rate (LRR) in locally advanced breast cancer. The Early Breast Cancer Trialist’ Collaborative Group (EBCTCG) demonstrated that PMRT resulted in a reduction in LRR after...

Notes

Conflict of interest

C. Matuschek, D. Krug, R.J. Klement and R. Baumann declare that they have no competing interests.

References

  1. 1.
    Abdel-Rahman O (2018) Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease: an individual patient data analysis of three clinical trials. Strahlenther Onkol.  https://doi.org/10.1007/s00066-018-1343-x CrossRefPubMedGoogle Scholar
  2. 2.
    Abdel-Rahman O, Cheung WY (2018) Impact of smoking history on the outcomes of women with early-stage breast cancer: a secondary analysis of a randomized study. Med Oncol 35:68CrossRefGoogle Scholar
  3. 3.
    Budach W, Bolke E, Kammers K et al (2015) Adjuvant radiation therapy of regional lymph nodes in breast cancer—a meta-analysis of randomized trials- an update. Radiat Oncol 10:258CrossRefGoogle Scholar
  4. 4.
    Early Breast Cancer Trialists’ Collaborative Group, Mcgale P, Taylor C et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383:2127–2135CrossRefGoogle Scholar
  5. 5.
    Eiermann W, Pienkowski T, Crown J et al (2011) Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2‑normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 29:3877–3884CrossRefGoogle Scholar
  6. 6.
    Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P et al (2012) Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 14:R70CrossRefGoogle Scholar
  7. 7.
    Mackey JR, Martin M, Pienkowski T et al (2013) Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14:72–80CrossRefGoogle Scholar
  8. 8.
    Mcbride A, Allen P, Woodward W et al (2014) Locoregional recurrence risk for patients with T1,2 breast cancer with 1–3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys 89:392–398CrossRefGoogle Scholar
  9. 9.
    Poortmans PM, Collette S, Kirkove C et al (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 373:317–327CrossRefGoogle Scholar
  10. 10.
    Whelan TJ, Olivotto IA, Parulekar WR et al (2015) Regional nodal irradiation in early-stage breast cancer. N Engl J Med 373:307–316CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Christiane Matuschek
    • 1
    Email author
  • David Krug
    • 2
    • 3
    • 6
  • Rainer J. Klement
    • 4
  • René Baumann
    • 5
    • 6
  1. 1.Klinik für Strahlentherapie und RadioonkologieMedical Faculty, Universitätsklinikum Düsseldorf, Heinrich-Heine UniversitätDüsseldorfGermany
  2. 2.RadioOnkologie und StrahlentherapieUniversitätsKlinikum HeidelbergHeidelbergGermany
  3. 3.National Center for Radiation Research in Oncology (NCRO)Heidelberg Institute for Radiation Oncology (HIRO)HeidelbergGermany
  4. 4.Klinik für Strahlentherapie und RadioonkologieLeopoldina Krankenhaus SchweinfurtSchweinfurtGermany
  5. 5.Klinik für RadioOnkologie und StrahlentherapieSt. Marienkrankenhaus SiegenSiegenGermany
  6. 6.Klinik für StrahlentherapieUniversitätsklinikum Schleswig-HolsteinKielGermany

Personalised recommendations